Clinical Scorecard: Evaluating the Readiness of Comprehensive Targeted Next-Generation Sequencing for Routine Use in ICU Patients with Severe Pneumonia

At a Glance

Key Highlights

• tNGS (RPIP) showed a 90.2% analytical detection rate versus 82.4% for standard testing (CMT + FAPP), but no significant difference in adjudicated causative pathogen identification.
• tNGS provided additional clinically actionable yield in 23.5% of patients, mainly through antimicrobial resistance gene detection.
• Challenges to routine ICU implementation include unclear optimal timing, limited use of AMR data for therapy guidance, high cost, long turnaround times, and interpretation complexities.

Guideline-Based Recommendations

Diagnosis

• Use tNGS as an adjunctive diagnostic tool alongside conventional microbiological tests and molecular assays.
• Consider multidisciplinary adjudication incorporating clinical, imaging, microbiological, and treatment response data for pathogen identification.
• Recognize that nearly half of severe pneumonia cases may remain without an identified causative pathogen even after comprehensive testing.

Management

• Apply tNGS-derived antimicrobial resistance information cautiously due to genotype-phenotype discrepancies.
• Use tNGS results to support antimicrobial stewardship and potential de-escalation, especially when noninfectious lung injury is suspected.
• Incorporate multidisciplinary review of negative molecular diagnostic results to avoid unnecessary broad-spectrum antibiotic use.

Monitoring & Follow-up

• Monitor turnaround time closely; current median analytical TAT (~6.5 days) limits tNGS as a same-day decision tool.
• Ensure strict standardization of sample collection to prevent contamination, particularly from non-sterile sites like BAL.
• Implement bioinformatic pipelines with rule-based stratification to improve specificity and interpretative accuracy.

Risks

• Potential for false positives due to environmental or reagent contamination ('kitome') and non-specific microbial signals.
• Limited clinical impact if tNGS results are not timely or if clinicians lack familiarity with interpreting molecular diagnostics.
• High cost and resource requirements may limit routine use without clear evidence of improved patient outcomes.

Patient & Prescribing Data

Critically ill adult ICU patients with severe pneumonia

tNGS can identify additional antimicrobial resistance determinants to inform therapy, but phenotypic susceptibility testing remains essential; multidisciplinary review is critical to optimize antimicrobial stewardship.

Clinical Best Practices

• Integrate tNGS with conventional microbiological and molecular testing rather than replacing them.
• Perform multidisciplinary clinical adjudication to interpret tNGS findings in context.
• Standardize sample collection and laboratory workflows to minimize contamination and variability.
• Aim to reduce turnaround time through optimized workflows and close clinical-laboratory collaboration.
• Use rule-based bioinformatic stratification to enhance specificity of pathogen detection in BAL samples.
• Consider host transcriptional profiling combined with metagenomic pathogen detection for future comprehensive sepsis diagnosis.

References

• Li et al. on molecular diagnostics barriers
• Wu et al. on clinical translation hurdles
• Chen et al. on diagnostic yield in immunocompromised patients
• Multicenter randomized controlled trial on NGS benefits
• Charalampous et al. on rapid respiratory metagenomics
• Kalantar et al. on integrating host transcriptional profiling
• Lai et al. on contamination sources in metagenomic NGS